Head-to-head evidence
baricitinib vs QLM3003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly
NCT03334396 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.
Next expected readout: May 2030 · NCT07262983 (registry estimate)
QLM3003
Developed by Qilu Pharmaceutical
NCT06058000 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and enrolled 120 participants, with a clinical disease-activity endpoint (EASI-75). However, no primary endpoint results or statistical comparison are available, so the trial provides well-designed but currently incomplete evidence.
Next expected readout: March 2027 · NCT06880276 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · QLM3003's landscape